Adenovirus vector-based vaccine for infectious diseases

Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5

Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102 · see citing works

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,063 · see citing works

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · see citing works

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259 · see citing works

Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment

Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199 · see citing works

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · see citing works

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713 · see citing works

CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.

Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055 · see citing works

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Muruve, D. A., Pétrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, R. J., & Tschopp, J. (2008) · Nature · doi:10.1038/nature06664 · Cited by 936 · see citing works

CD46 is a cellular receptor for group B adenoviruses

Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 793 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

McElrath, M. J., Rosa, S. C. D., Moodie, Z., Dubey, S. A., Kierstead, L. S., Janes, H., Defawe, O., Carter, D. K., Hural, J., Akondy, R. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 712 · see citing works

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction

Cohen, C. J., Shieh, J. T. C., Pickles, R. J., Okegawa, T., Hsieh, J., & Bergelson, J. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261452898 · Cited by 702 · see citing works

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M. K., Greig, J. A., Denby, L., et al. (2008) · Cell · doi:10.1016/j.cell.2008.01.016 · Cited by 644 · see citing works

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603 · see citing works

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

Mallery, D. L., McEwan, W. A., Bidgood, S. R., Towers, G. J., Johnson, C. M., & James, L. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014074107 · Cited by 517 · see citing works

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503 · see citing works

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 490 · see citing works

Anticipating the international spread of Zika virus from Brazil

Bogoch, I. I., Brady, O. J., Kraemer, M. U. G., German, M. L., Creatore, M., Kulkarni, M. A., Brownstein, J. S., Mekaru, S. R., Hay, S. I., Groot, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00080-5 · Cited by 464 · see citing works

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14

Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M. R., Strauss, R., Zhang, X., et al. (2010) · Nature Medicine · doi:10.1038/nm.2270 · Cited by 436 · see citing works

Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors

Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 427 · see citing works

PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo

O’Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409 · see citing works

Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism

Krasnykh, V. N., Mikheeva, G., Douglas, J. T., & Curiel, D. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6839-6846.1996 · Cited by 387 · see citing works

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

Dicks, M. D. J., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V. S., & Cottingham, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040385 · Cited by 384 · see citing works

Basolateral Localization of Fiber Receptors Limits Adenovirus Infection from the Apical Surface of Airway Epithelia

Walters, R. W., Grunst, T., Bergelson, J. M., Finberg, R. W., Welsh, M. J., & Zabner, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10219 · Cited by 372 · see citing works

ISOLATION AND PARTIAL CHARACTERISATION OF A NEW VIRUS CAUSING ACUTE HÆMORRHAGIC FEVER IN ZAIRE

Johnson, K. M., Lange, J., Webb, P. A., & Murphy, F. A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92000-1 · Cited by 371 · see citing works

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., PETER, T. F., Peyerl, F. W., Kishko, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369 · see citing works

Efficient Gene Transfer into Human CD34 + Cells by a Retargeted Adenovirus Vector

Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., & Lieber, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2567-2583.2000 · Cited by 367 · see citing works

Adenovirus Type 11 Uses CD46 as a Cellular Receptor

Segerman, A., Atkinson, J. P., Marttila, M., Dennerquist, V., Wadell, G., & Arnberg, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9183-9191.2003 · Cited by 358 · see citing works

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Stanley, D. A., Honko, A. N., Asiedu, C. K., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L. E., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350 · see citing works

Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor

Arnberg, N., Edlund, K., Kidd, A. H., & Wadell, G. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.42-48.2000 · Cited by 316 · see citing works

The role of the nuclear pore complex in adenovirus DNA entry

Greber, U. F., Suomalainen, M., Stidwill, R. P., Boucke, K., Ebersold, M. W., & Helenius, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5998 · Cited by 299 · see citing works

Replication-Defective Vector Based on a Chimpanzee Adenovirus

Farina, S. F., Gao, G., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J. A., Ertl, H. C. J., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11603-11613.2001 · Cited by 271 · see citing works

Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

Nwanegbo, E. C., Vardas, E., Gao, W., Whittle, H. C., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. A. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.2.351-357.2004 · Cited by 266 · see citing works

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · doi:10.1101/2020.05.13.093195 · Cited by 246 · see citing works

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans

Kampen, K. R. V., Shi, Z., Gao, P., Zhang, J., Foster, K. W., Chen, D., Marks, D. H., Elmets, C. A., & Tang, D.-C. C. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.043 · Cited by 220 · see citing works

Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo

Appledorn, D. M., Patial, S., McBride, A. J., Godbehere, S., van Rooijen, N., Parameswaran, N., & Amalfitano, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2134 · Cited by 198 · see citing works

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Zhu, F., Hou, L., Li, J., Wu, S., Liu, P., Zhang, G., Hu, Y., Meng, F., Xu, J., Tang, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60553-0 · Cited by 184 · see citing works

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

Gray, G., Buchbinder, S., & Duerr, A. C. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d2b · Cited by 172 · see citing works

Mapping and role of T cell response in SARS-CoV-2–infected mice

Zhuang, Z., Lai, X., Sun, J., Chen, Z., Zhang, Z., Dai, J., Liu, D., Li, Y., Li, F., Wang, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202187 · Cited by 171 · see citing works

Expression of the Primary Coxsackie and Adenovirus Receptor Is Downregulated during Skeletal Muscle Maturation and Limits the Efficacy of Adenovirus-Mediated Gene Delivery to Muscle Cells

Nalbantoglu, J. N., Pari, G., Karpati, G., & Holland, P. C. (1999) · Human Gene Therapy · doi:10.1089/10430349950018409 · Cited by 169 · see citing works

A Single Intranasal or Intramuscular Immunization with Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters

Bricker, T. L., Darling, T. L., Hassan, A. O., Harastani, H., Soung, A., Jiang, X., Dai, Y.-N., Zhao, H., Adams, L. J., Holtzman, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109400 · Cited by 168 · see citing works

Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5

Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J. M., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A. A. C., Gillissen, G. F., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13207-13215.2004 · Cited by 148 · see citing works

Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae

Chen, H., Xiang, Z., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D., Hutnick, N. A., Yuan, S., Gray, C., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00450-10 · Cited by 145 · see citing works

Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors

Cerullo, V., Seiler, M. P., Mane, V. P., Brunetti‐Pierri, N., Clarke, C., Bertin, T., Rodgers, J. R., & Lee, B. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300031 · Cited by 143 · see citing works

Adenovirus Vaccines in the U.S. Military

Gaydos, C. A., & Gaydos, J. C. (1995) · Military Medicine · doi:10.1093/milmed/160.6.300 · Cited by 139 · see citing works

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

Coughlan, L., Sridhar, S., Payne, R., Edmans, M. D., Milicic, A., Venkatraman, N., Lugonja, B., Clifton, L., Qi, C., Folegatti, P. M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.02.011 · Cited by 138 · see citing works

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C. L., Silva-Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S. K., Oguti, B., et al. (2021) · Science · doi:10.1126/science.aax8819 · Cited by 130 · see citing works

Bilamellar Cationic Liposomes Protect Adenovectors from Preexisting Humoral Immune Responses

Yotnda, P., Chen, D.-H., Chiu, W., Piedra, P. A., Davis, A. R., Templeton, N. S., & Brenner, M. K. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0545 · Cited by 113 · see citing works

Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon

Roy, S., Shirley, P. S., McClelland, A., & Kaleko, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6875-6879.1998 · Cited by 111 · see citing works

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling

Quinn, K. M., Zak, D. E., Costa, A. D. S., Yamamoto, A., Kastenmüller, K., Hill, B. J., Lynn, G. M., Darrah, P. A., Lindsay, R. W. B., Wang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78280 · Cited by 110 · see citing works

Identification and quantification of complement regulator CD46 on normal human tissues.

Johnstone, R. W., Loveland, B. E., & McKenzie, I. F. C. (1993) · PubMed · Cited by 108 · see citing works

Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9‐dependent maturation and IFN‐α production

Basner‐Tschakarjan, E., Gaffal, E., O’Keeffe, M. A., Tormo, D., Limmer, A., Wagner, H., Hochrein, H., & Tüting, T. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.964 · Cited by 102 · see citing works

Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector

Stone, D., Ni, S., Li, Z.-Y., Gaggar, A., Paolo, N. C. D., Feng, Q., Sandig, V., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5090-5104.2005 · Cited by 102 · see citing works

Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector

Sakurai, F., Mizuguchi, H., Yamaguchi, T., & Hayakawa, T. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00243-0 · Cited by 100 · see citing works

Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy

Li, R., Xiaohua, T., Li, Y., Zhang, H., Ma, R., Ji, T., Dong, W., Tong, T., Liu, Y., Chen, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.025 · Cited by 100 · see citing works

Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor

Baker, A. T., Mundy, R. M., Davies, J. A., Rizkallah, P. J., & Parker, A. L. (2019) · Science Advances · doi:10.1126/sciadv.aax3567 · Cited by 92 · see citing works

Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector

Sakurai, F., Mizuguchi, H., & Hayakawa, T. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301959 · Cited by 88 · see citing works

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Baden, L. R., Stieh, D. J., Sarnecki, M., Walsh, S. R., Tomaras, G. D., Kublin, J. G., McElrath, M. J., Alter, G., Ferrari, G., Montefiori, D. C., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30229-0 · Cited by 88 · see citing works

Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors

Yamaguchi, T., Kawabata, K., Koizumi, N., Sakurai, F., Kaneda‐Nakashima, K., Sakurai, H., Sasaki, T., Okada, N., Yamanishi, K., & Mizuguchi, H. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.016 · Cited by 87 · see citing works

Adenovirus Virus-Associated RNAs Induce Type I Interferon Expression through a RIG-I-Mediated Pathway

Minamitani, T., Iwakiri, D., & Takada, K. (2011) · Journal of Virology · doi:10.1128/jvi.02160-10 · Cited by 87 · see citing works

Innate immunity to adenovirus: lessons from mice

Atasheva, S., Yao, J., & Shayakhmetov, D. M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13696 · Cited by 87 · see citing works

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity

Lemckert, A. A. C., Grimbergen, J. M., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P. H. A., Goudsmit, J., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.82079-0 · Cited by 85 · see citing works

A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity

Matsuda, K., Migueles, S. A., Huang, J., Bolkhovitinov, L., Stuccio, S., Griesman, T., Pullano, A. A., Kang, B. H., Ishida, E., Zimmerman, M. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140794 · Cited by 83 · see citing works

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Salisch, N. C., Stephenson, K. E., Williams, K. L., Cox, F., van der Fits, L., Heerwegh, D., Truyers, C., Habets, M. N., Kanjilal, D. G., Larocca, R. A., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5306 · Cited by 81 · see citing works

A Recombinant E1-Deleted Canine Adenoviral Vector Capable of Transduction and Expression of a Transgene in Human-Derived Cells and In Vivo

Klonjkowski, B., Gilardi‐Hebenstreit, P., Hadchouel, J., Randrianarison-Huetz, V., Boutin, S., Yeh, P., Perricaudet, M., & Kremer, E. J. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.17-2103 · Cited by 80 · see citing works

Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient

Hage, E., Liebert, U. G., Bergs, S., Ganzenmueller, T., & Heim, A. (2015) · Journal of General Virology · doi:10.1099/vir.0.000196 · Cited by 80 · see citing works

Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors

Rhee, E. G., Blattman, J. N., Kasturi, S. P., Kelley, R., Kaufman, D. R., Lynch, D. M., Porte, A. L., Simmons, N. L., Clark, S., Pulendran, B., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01597-10 · Cited by 79 · see citing works

Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage

Xu, K., Song, Y., Dai, L., Zhang, Y., Lu, X., Xie, Y., Zhang, H., Tao, C., Wang, Q., Huang, Q., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01722-17 · Cited by 76 · see citing works

Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

Cheng, C., Gall, J. G. D., Nason, M., King, C. R., Koup, R. A., Roederer, M., McElrath, M. J., Morgan, C. A., Churchyard, G., Baden, L. R., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00866-09 · Cited by 75 · see citing works

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Hayton, E., Rose, A., Ibrahimsa, U., Sorbo, M. D., Capone, S., Crook, A., Black, A. P., Dorrell, L., & Hanke, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101591 · Cited by 74 · see citing works

Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine againstPlasmodium yoeliiin Mice

Ophorst, O. J. A. E., Radošević, K., Havenga, M. J. E., Pau, M. G., Holterman, L., Berkhout, B., Goudsmit, J., & Tsuji, M. (2005) · Infection and Immunity · doi:10.1128/iai.74.1.313-320.2006 · Cited by 73 · see citing works

Trafficking of Antigen-Specific CD8+ T-Lymphocytes to Mucosal Surfaces Following Intramuscular Vaccination

Kaufman, D., Liu, J.-Y., Carville, A., Mansfield, K., Havenga, M., Goudsmit, J., & Barouch, D. (2008) · Journal of Immunology · doi:10.4049/jimmunol.181.6.4188 · Cited by 72 · see citing works

Induction of type I interferon by adenovirus-encoded small RNAs

Yamaguchi, T., Kawabata, K., Kouyama, E., Ishii, K. J., Katayama, K., Suzuki, T., Kurachi, S., Sakurai, F., Akira, S., & Mizuguchi, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009823107 · Cited by 66 · see citing works

Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8 + T Lymphocytes

Kaufman, D. R., Bivas‐Benita, M., Simmons, N. L., Miller, D. D., & Barouch, D. H. (2010) · Journal of Virology · doi:10.1128/jvi.02563-09 · Cited by 66 · see citing works

Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans

Baden, L. R., Liu, J., Li, H., Johnson, J. A., Walsh, S. R., Kleinjan, J. A., Engelson, B. A., Peter, L. E., Abbink, P., Milner, D. A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu485 · Cited by 66 · see citing works

Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity

Anghelina, D., Lam, E., & Falck-Pedersen, E. (2016) · Journal of Virology · doi:10.1128/jvi.00500-16 · Cited by 59 · see citing works

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

Volkmann, A., Williamson, A., Weidenthaler, H., Meyer, T. P. H., Robertson, J. S., Excler, J., CONDIT, R. C., Evans, E., Smith, E. R., Kim, D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.050 · Cited by 58 · see citing works

Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives

Dhama, K., Malik, Y. S., Malik, S. V. S., & Singh, R. K. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6197 · Cited by 57 · see citing works

Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models

Guo, Q., Chan, J. F., Poon, V. K., Wu, S., Chan, C. C., Hou, L., Yip, C. C., Ren, C., Cai, J., Zhao, M., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy187 · Cited by 56 · see citing works

Membrane Cofactor Protein (CD46) Is a Basolateral Protein That Is Not Endocytosed

Maisner, A., Zimmer, G., Liszewski, M. K., Lublin, D. M., Atkinson, J. P., & Herrler, G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20793 · Cited by 46 · see citing works

Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route

Patterson, L. J., Kuate, S., Daltabuit-Test, M., Li, Q., Xiao, P., McKinnon, K. M., DiPasquale, J., Cristillo, A. D., Venzon, D. J., Haase, A. T., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00010-12 · Cited by 46 · see citing works

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Hwang, J., Lee, S. B., Lee, S. W., Lee, M. H., Koyanagi, A., Jacob, L., Tizaoui, K., Yon, D. K., Shin, J. I., & Smith, L. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102681 · Cited by 45 · see citing works

Anionic Liposomes Increase the Efficiency of Adenovirus-Mediated Gene Transfer to Coxsackie-Adenovirus Receptor Deficient Cells

Zhong, Z., Shi, S., Han, J., Zhang, Z., & Sun, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900151k · Cited by 44 · see citing works

Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16–STING–Type I IFN Pathway and AIM2 Sensor

Liu, F., Niu, Q., Fan, X., Liu, C., Zhang, J., Wei, Z., Hou, W., Kanneganti, T., Robb, M. L., Kim, J. H., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700698 · Cited by 44 · see citing works

Creation of a panel of vectors based on ape adenovirus isolates

Roy, S., Medina‐Jaszek, A., Wilson, M. J., Sandhu, A. K., Calcedo, R., Lin, J., & Wilson, J. M. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1530 · Cited by 43 · see citing works

Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles

Kakiuchi, Y., Kuroda, S., Kanaya, N., Kumon, K., Tsumura, T., Hashimoto, M., Yagi, C., Sugimoto, R., Hamada, Y., Kikuchi, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.015 · Cited by 42 · see citing works

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Sørensen, A. L. T., Rolland, M., Hartmann, J. P., Harboe, Z. B., Roed, C., Jensen, T. Ø., Kolte, L., Fassi, D. E., Hillingsø, J., Radziwon‐Balicka, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004904 · Cited by 41 · see citing works

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor

Zhang, Y., Wu, J., Zhang, H., Wei, J., & Wu, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.574007 · Cited by 40 · see citing works

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge

Park, K. S., Lee, J., Ahn, S. S., Byun, Y.-H., Seong, B. L., Baek, Y. H., Song, M., Choi, Y. K., Na, Y. J., Hwang, I., et al. (2009) · Virology · doi:10.1016/j.virol.2009.09.018 · Cited by 39 · see citing works

Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

Barouch, D. H., Liu, J., Lynch, D. M., O’Brien, K. L., Porte, A. L., Simmons, N. L., Riggs, A. M., Clark, S., Abbink, P., Montefiori, D. C., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00821-09 · Cited by 36 · see citing works

TRIF, and TRIF-Interacting TLRs Differentially Modulate Several Adenovirus Vector-Induced Immune Responses

Appledorn, D., Patial, S., Godbehere, S., Parameswaran, N., & Amalfitano, A. (2009) · Journal of Innate Immunity · doi:10.1159/000207194 · Cited by 34 · see citing works

Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors

Verhaagh, S., de Jong, E., Goudsmit, J., Lecollinet, S., Gillissen, G. F., de Vries, M. R., van Leuven, K., Que, I., Ouwehand, K., Mintardjo, R., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81293-0 · Cited by 30 · see citing works

Lactoferrin Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated Pyroptotic Response in Human Phagocytes

Chéneau, C., Eichholz, K., Tran, T. H., Tran, T. T. P., Paris, O., Henriquet, C., Bajramovic, J. J., Pugnière, M., & Kremer, E. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685218 · Cited by 30 · see citing works

A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development

Luo, S., Zhang, P., Ma, X., Wang, Q., Lu, J., Liu, B., Zhao, W., Allain, J., Li, C.-Y., & Li, T. (2019) · Virus Research · doi:10.1016/j.virusres.2019.05.008 · Cited by 23 · see citing works

Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines

Fukuhara, H., Hayashi, Y., Yamamoto, N., Fukui, T., Nishikawa, M., Mitsudo, K., Tohnai, I., Ueda, M., Mizuno, M., & Yoshida, J. (2003) · Oral Oncology · doi:10.1016/s1368-8375(03)00047-2 · Cited by 21 · see citing works

Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction

Suzuki‐Kouyama, E., Katayama, K., Sakurai, F., Yamaguchi, T., Kurachi, S., Kawabata, K., Nakagawa, S., & Mizuguchi, H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.060 · Cited by 18 · see citing works

Humoral Responses Elicited by Adenovirus Displaying Epitopes Are Induced Independently of the Infection Process and Shaped by the Toll-Like Receptor/MyD88 Pathway

Anchim, A., Raddi, N., Zig, L., Perrieau, P., Goffic, R. L., Ryffel, B., & Benihoud, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00124 · Cited by 14 · see citing works

T Helper 17 Promotes Induction of Antigen-Specific Gut-Mucosal Cytotoxic T Lymphocytes following Adenovirus Vector Vaccination

Hemmi, M., Tachibana, M., Fujimoto, N., Shoji, M., Sakurai, F., Kobiyama, K., Ishii, K. J., Akira, S., & Mizuguchi, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01456 · Cited by 11 · see citing works

A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X

Matsui, H., Sakurai, F., Katayama, K., Yamaguchi, T., Okamoto, S., Takahira, K., Tachibana, M., Nakagawa, S., & Mizuguchi, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.011 · Cited by 10 · see citing works

Type-I IFN signaling is required for the induction of antigen-specific CD8+ T cell responses by adenovirus vector vaccine in the gut-mucosa

Shoji, M., Tachibana, M., Katayama, K., Tomita, K., Tsuzuki, S., Sakurai, F., Kawabata, K., Ishii, K. J., Akira, S., & Mizuguchi, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.056 · Cited by 8 · see citing works

Downregulation of CD46 During Muscle Differentiation: Implications for Gene Transfer to Human Skeletal Muscle Using Group B Adenoviruses

Larochelle, N., Deol, J. R., Srivastava, V. K., Allen, C. A., Mizuguchi, H., Karpati, G., Holland, P. C., & Nalbantoglu, J. N. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.040 · Cited by 7 · see citing works

Influenza vaccine for 2020-2021.

(2020) · PubMed · Cited by 3 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 222 · see citing works

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H. I., Severino, P. B., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.04.010 · Cited by 182 · see citing works

Two centuries of vaccination: historical and conceptual approach and future perspectives

Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 160 · see citing works

Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines

Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 138 · see citing works

Adenoviruses in medicine: innocuous pathogen, predator, or partner

MacNeil, K. M., Dodge, M. J., Evans, A. M., Tessier, T. M., Weinberg, J. B., & Mymryk, J. S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.001 · Cited by 91 · see citing works

Vaccine Strategies to Elicit Mucosal Immunity

Song, Y., Mehl, F., & Zeichner, S. L. (2024) · Vaccines · doi:10.3390/vaccines12020191 · Cited by 80 · see citing works

Oral Vaccines: A Better Future of Immunization

Kwong, K. W.-Y., Xin, Y., Lai, N. C.-Y., Sung, J. C.-C., Wu, K.-C., Hamied, Y. K., Sze, E. T.-P., & Lam, D. M. (2023) · Vaccines · doi:10.3390/vaccines11071232 · Cited by 74 · see citing works

Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history

Kiszel, P., Sík, P., Miklós, J., Kajdácsi, E., Sinkovits, G., Cervenak, L., & Prohászka, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-40103-x · Cited by 69 · see citing works

Nasal vaccines for respiratory infections

Kiyono, H., & Ernst, P. B. (2025) · Nature · doi:10.1038/s41586-025-08910-6 · Cited by 58 · see citing works

Nasal vaccines: solutions for respiratory infectious diseases

Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y., & Kiyono, H. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.009 · Cited by 54 · see citing works

Development of Nasal Vaccines and the Associated Challenges

Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 48 · see citing works

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines

Trivedi, P. D., Byrne, B. J., & Corti, M. (2023) · Viruses · doi:10.3390/v15122378 · Cited by 46 · see citing works

CCHFV vaccine development, current challenges, limitations, and future directions

Ahata, B., & Akçapınar, G. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238882 · Cited by 40 · see citing works

Clinical Application of Adenovirus (AdV): A Comprehensive Review

Salauddin, M., Saha, S., Hossain, M. G., Okuda, K., & Shimada, M. (2024) · Viruses · doi:10.3390/v16071094 · Cited by 36 · see citing works

Glycan masking in vaccine design: Targets, immunogens and applications

Martina, C. E., Crowe, J. E., & Meiler, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126034 · Cited by 34 · see citing works

Swine influenza A virus: challenges and novel vaccine strategies

Petro-Turnquist, E. M., Pekarek, M. J., & Weaver, E. A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1336013 · Cited by 34 · see citing works

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

Scarsella, L., Ehrke‐Schulz, E., Paulussen, M., Thal, S. C., Ehrhardt, A., & Aydin, M. (2024) · Viruses · doi:10.3390/v16030377 · Cited by 23 · see citing works

Cancer mRNA vaccines: clinical application progress and challenges

Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 24 · see citing works

Current Advances in Viral Nanoparticles for Biomedicine

Sun, X., Tian, T., Lian, Y., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c13146 · Cited by 21 · see citing works

Identification of Inhibitors and Drug Targets for Human Adenovirus Infections

Liu, M., Jiang, L., Cao, W., Wu, J., & Chen, X. (2022) · Viruses · doi:10.3390/v14050959 · Cited by 19 · see citing works

A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov

Wang, S., Liu, W.-Q., Li, Y., Li, J., & Zhu, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2242528 · Cited by 18 · see citing works

Novel technologies are turning a dream into reality: conditionally replicating viruses as vaccines

Tang, Y., Yu, C., & Cai, X. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.09.002 · Cited by 19 · see citing works

Progress in African Swine Fever Vector Vaccine Development

Yang, Y., Yuan, H., Zhang, Y., Luan, J., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030921 · Cited by 18 · see citing works

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

Cohen, G., Jungsomsri, P., Sangwongwanich, J., Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052525 · Cited by 17 · see citing works

Adenovirus-Based Gene Therapy for Bone Regeneration: A Comparative Analysis of In Vivo and Ex Vivo BMP2 Gene Delivery

Bukharova, T. B., Nedorubova, I. A., Mokrousova, V., Meglei, A. Y., Basina, V. P., Nedorubov, A. A., Vasilyev, A. V., Grigoriev, T. E., Zagoskin, Y. D., Чвалун, С. Н., et al. (2023) · Cells · doi:10.3390/cells12131762 · Cited by 17 · see citing works

In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection

Tkaczyk, C., Newton, M. R., Patnaik, M. M., Thom, G., Strain, M., Gamson, A., Daramola, O., Murthy, A., Douthwaite, J. A., Stepanov, O., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.036 · Cited by 16 · see citing works

Vaccine formulation design: challenges and opportunities

Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 16 · see citing works

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Rzymski, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183258 · Cited by 16 · see citing works

DEC-205 receptor targeted poly(lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease vaccine in mice

Feng, Y., Fan, J., Wu, D., Liu, Q., Li, H., Zhang, X., Li, S., Tang, F. R., Liu, Z., Zhang, L., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.158 · Cited by 15 · see citing works

Revolutionizing antiviral therapy with nanobodies: Generation and prospects

Mustafa, M. I., & Mohammed, A. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00803 · Cited by 14 · see citing works

Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection

Gao, A., Chen, Y., Liang, H., Cui, X., Zhang, A., & Cui, D. (2023) · Theranostics · doi:10.7150/thno.83390 · Cited by 14 · see citing works

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 15 · see citing works

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial

Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., Auewarakul, C. U., & Mahanonda, N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.019 · Cited by 14 · see citing works

Mucosal Vaccination: A Promising Alternative Against Flaviviruses

Lurı́a-Pérez, R., Sánchez-Vargas, L. A., Muñoz-López, P., & Mellado‐Sánchez, G. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.887729 · Cited by 13 · see citing works

Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses

Jang, H., Matsuoka, M., & Freire, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220610 · Cited by 13 · see citing works

Vaccine Development for Human Leishmaniasis

Clímaco, M. D. C., Kraemer, L. R., & Fujiwara, R. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-24355-4_14 · Cited by 13 · see citing works

mRNA vaccines: a transformative technology with applications beyond COVID ‐19

Overmars, I., Au‐Yeung, G., Nolan, T. M., & Steer, A. C. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51620 · Cited by 12 · see citing works

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

Khan, S., Salisch, N. C., Gil, A. I., Boedhoe, S., Boer, K. F.-D., Serroyen, J., Schuitemaker, H., & Zahn, R. C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00567-w · Cited by 12 · see citing works

Pharmaceutical strategies for optimized mRNA expression

Shi, Y., Mao, J., Wang, S., Ma, S., Luo, L., & You, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122853 · Cited by 11 · see citing works

Adenoviral Vectors for Gene Therapy of Hereditary Diseases

Muravyeva, A., & Smirnikhina, S. (2024) · Biology · doi:10.3390/biology13121052 · Cited by 11 · see citing works

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

Farhad, T., Neves, K., Arbuthnot, P. B., & Maepa, M. B. (2022) · Genes · doi:10.3390/genes13111941 · Cited by 11 · see citing works

Liver Transaminases in Pediatric Adenovirus Infection—A Five-Year Study in Two Major Reference Centers from Romania

Săndulescu, O., Streinu-Cercel, A., Miron, V. D., Covăcescu, M., Streinu‐Cercel, A., & Craiu, M. (2023) · Microorganisms · doi:10.3390/microorganisms11020302 · Cited by 9 · see citing works

Time trend of respiratory viruses before and during the COVID‐19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022

Kindi, H. A., Meredith, L. W., Al‐Jardani, A., Sajina, F., Al-Shukri, I., al Haj, R., Alyaquobi, F., Wahaibi, A. S. A., & Al-Maani, A. S. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13233 · Cited by 9 · see citing works

SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis

Angues, R. V., & Bustos, Y. P. (2023) · Cureus · doi:10.7759/cureus.50703 · Cited by 9 · see citing works

COVID-19 Vaccines in Children

Fayad, D., & Frenck, R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010087 · Cited by 9 · see citing works

Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production

Sun, Y., Huang, L., Nie, J., Feng, K., Liu, Y., & Bai, Z. (2022) · AMB Express · doi:10.1186/s13568-022-01398-7 · Cited by 8 · see citing works

Integrating Affinity Chromatography in the Platform Process for Adenovirus Purification

Wu, Y., Barbieri, E., Smith, W. K., Minzoni, A., Kilgore, R., Chu, W., Daniele, M. A.-A., & Menegatti, S. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.29006 · Cited by 7 · see citing works

Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease

Wang, N., & Wang, T. (2024) · Biotechnology Journal · doi:10.1002/biot.202300658 · Cited by 10 · see citing works

Self-Adjuvanting Adenoviral Nanovaccine for Effective T-Cell-Mediated Immunity and Long-Lasting Memory Cell Activation against Tuberculosis

Sowndharya, C. K., Mehnath, S., Ponbharathi, A., & Jeyaraj, M. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00619 · Cited by 7 · see citing works

Monkeypox outbreak: after COVID-19, another challenge for the hemostatic system?

Marietta, M., Coluccio, V., & Luppi, M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03112-8 · Cited by 7 · see citing works

One HA stalk topping multiple heads as a novel influenza vaccine

Zhou, P., Qiu, T., Wang, X., Yang, X., Shi, H., Zhu, C., Dai, W., Xing, M., Zhang, X., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2290838 · Cited by 7 · see citing works

HEHR: Homing Endonuclease-Mediated Homologous Recombination for Efficient Adenovirus Genome Engineering

Schröer, K., Arakrak, F., Bremke, A., Ehrhardt, A., & Zhang, W.-L. (2022) · Genes · doi:10.3390/genes13112129 · Cited by 4 · see citing works

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 7 · see citing works

Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5

Sallard, E., Schulte, L., van den Boom, A., Klimovitskii, A. E., Knierer, J., Hagedorn, C., Knocks, M., Zhang, W., Kreppel, F., Ehrhardt, A., et al. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3576 · Cited by 6 · see citing works

Recent Advances in Vaccine Adjuvants: From Lab to Clinic

Vardikar, A., Prajapati, M. K., Gholap, A. D., Rojekar, S. V., Keshari, R., Jain, H., & Rajput, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126180 · Cited by 5 · see citing works

Gene therapies for osteoarthritis: progress and prospects

Defois, A., Bon, N., Mével, M., Deniaud, D., Maugars, Y., Guicheux, J., Adjali, O., & Vinatier, C. S. (2024) · Journal of Cartilage & Joint Preservation · doi:10.1016/j.jcjp.2024.100186 · Cited by 5 · see citing works

ADEVO: Proof-of-concept of adenovirus-directed EVOlution by random peptide display on the fiber knob

Sallard, E., Fischer, J., Schröer, K., Dawson, L.-M., Beaude, N., Affes, A., Ehrke‐Schulz, E., Zhang, W., Westhaus, A., Cabanes‐Creus, M., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200867 · Cited by 5 · see citing works

Adenovirus type 34 and HVR1-deleted Adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis riskPreprint

Sallard, E., Pembaur, D., Schröer, K., Schellhorn, S., Koukou, G., Schmidt, N., Zhang, W., Kreppel, F., & Ehrhardt, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.07.515483 · Cited by 5 · see citing works

Engineering immune cells for next-generation therapies

Han, M., Lou, J., Pan, M., Xu, S., Jiang, X., & Jing, W. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115012 · Cited by 4 · see citing works

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi, R., Ikemoto, S., Shiota, A., Tsukamoto, T., Asayama, A., Tachibana, M., Sakurai, F., & Mizuguchi, H. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124480 · Cited by 4 · see citing works

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials

Liu, W., Li, Y., Li, X., Wang, F., Qi, R., Zhu, T., & Li, J. (2025) · Vaccines · doi:10.3390/vaccines13030333 · Cited by 4 · see citing works

Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein

Wang, Y., Yang, L., Tang, K., Zhang, Y., Zhang, C., Zhang, Y., Jin, B., Zhang, Y., Zhuang, R., & Ma, Y. (2023) · Viruses · doi:10.3390/v16010052 · Cited by 4 · see citing works

Regulation of protein thermal stability and its potential application in the development of thermo-attenuated vaccines

Wang, M., Wu, C., Liu, N., Jiang, X., Dong, H., Zhao, S., Li, C., Xu, S., & Gu, L. (2024) · Engineering Microbiology · doi:10.1016/j.engmic.2024.100162 · Cited by 4 · see citing works

Effects of Common Anti-Inflammatories on Adenovirus Entry and Their Physicochemical Properties: An In-Depth Study Using Cellular and Animal Models

Galván‐Salazar, H. R., Delgado‐Machuca, M., Hernández‐Fuentes, G. A., Aurelien-Cabezas, N. S., Rodríguez‐Hernández, A., Veloz, I. G., Mendoza-Hernandez, M. A., Martínez‐Fierro, M. L., Zaizar-Fregoso, S. A., Rodriguez-Sanchez, I. P., et al. (2024) · Microbiology Research · doi:10.3390/microbiolres15030105 · Cited by 4 · see citing works

How well do different COVID-19 vaccines protect against different viral variants? A systematic review and meta-analysis

Hoang, T. N. A., Byrne, A., Quach, H., Bannister-Tyrrell, M., & VOGT, F. M. (2024) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trae082 · Cited by 4 · see citing works

Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice

Voronina, D. V., Викторовна, В. И., Zubkova, O. V., Ozharovskaia, T. A., Popova, O. D., Chugunova, A. S., Павловна, Г. П., Игоревич, З. Д., Savina, D. M., Favorskaya, I. A., et al. (2025) · Viruses · doi:10.3390/v17081085 · Cited by 3 · see citing works

Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR

Tanaka, Y., Hamano, S., Ishii‐Watabe, A., Saito, Y., & Kikura‐Hanajiri, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101549 · Cited by 3 · see citing works

Heterologous DNA–Adenovirus Prime–Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge

Nogales‐Altozano, P., Gómez‐Marcos, L., Carlón, A. B., Louloudes-Lázaro, A., Rivera-Rodríguez, A., Larraga, J., Alcolea, P. J., Alonso, A., Larraga, V., Martı́n, V., et al. (2025) · Vaccines · doi:10.3390/vaccines13090991 · Cited by 3 · see citing works

Comprehensive review on COVID-19: etiology, pathogenicity, and treatment

Zawily, A. E., Eckert, S., Adajar, R. C., Wagih, N., Elmaidomy, A. H., Helmy, A. M., Mustafa, M., Elshorbagi, M., Ghali, E., Fadl, R. G., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1569013 · Cited by 3 · see citing works

Microneedles Based Thermally Stable Ad‐5 Viral Vector for Vaccine Delivery

Singh, P., Sharma, N., Huang, F., Bhaskar, N., Akbaba, H., Park, J., Radhakrishnan, A., Sakhrie, A., Nguyen, L., Ge, G., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504342 · Cited by 3 · see citing works

Mucosal immunity and vaccine development

Hong, W., Alu, A., Zhang, Z., Zhang, Y. L., He, X., Xu, L., Li, M., He, W., & Wang, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02687-4 · Cited by 3 · see citing works

A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine

Li, X., Peng, Q., Liu, X., Xu, H., Liu, J., Wu, X., Ye, Q., Li, M., & Li, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374486 · Cited by 3 · see citing works

Oral Ad5 Vector‐Based SARS‐CoV‐2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice

Mao, T., Zhang, P., Jiang, S., Li, D.-D., Li, J., Zhang, Q., Wang, H., Kong, X., & Duan, Z. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70236 · Cited by 3 · see citing works

A Critical Assessment of COVID-19 Genomic Vaccines

Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 3 · see citing works

HeterologousPrime-Boost immunizationwithAdenoviral vector and recombinant subunit vaccines strategies against dengue virus type2

Shoushtari, M. M., Salehi-Vaziri, ‪., Kadkhodazadeh, M., Teimoori, A., Arashkia, A., Roohvand, F., Teimoori‐Toolabi, L., Pouriayevali, M. H., & Azadmanesh, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114032 · Cited by 3 · see citing works

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Tica, J., Rezelj, V. V., Baron, B., van Paassen, V., Zaidman, J., Fairlie, L., Scheper, G. C., Gars, M. L., Struyf, F., Douoguih, M., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2450120 · Cited by 3 · see citing works

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo

Quentin-Froignant, C., Tollefson, A. E., Cline-Smith, A., Kappler‐Gratias, S., Landrein, N., Roy, V., Agrofoglio, L. A., Tóth, K., Wodrich, H., & Gallardo, F. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00170 · Cited by 3 · see citing works

Genetically Mediated Cell Membrane Engineering Strategies and Their Scope in Biomedical Applications

Tollabi, M., Kheirandish, M. H., Mehrabi, A., Poursalehi, Z., Heidari, M., & Milan, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-93425-4_6 · Cited by 2 · see citing works

Development and immunogenicity of adenoviral Fc-fused FMDV virus-like particle vaccine in swine

Park, J., Lee, H., Kang, K.-J., Jung, M. K., Mun, J. Y., Kim, M., Pyun, J., Hwang, S. Y., Park, J.-H., & Shin, H.-J. (2025) · Veterinary Quarterly · doi:10.1080/01652176.2025.2564443 · Cited by 2 · see citing works

The path from early- to late-liver stage arresting genetically attenuated parasites as a malaria vaccination strategy

Lamers, O. A. C., Franke-Fayard, B. M. D., Roestenberg, M., & Krol, J. M. M. (2025) · npj Vaccines · doi:10.1038/s41541-025-01265-z · Cited by 2 · see citing works

Application of biomimetic approaches in the treatment of neurological disorders

Sun, J., Li, H., Wang, J., & Yang, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102334 · Cited by 2 · see citing works

Enhancing the breadth of protection in mice with a multivalent influenza vaccine

Wang, X., Niu, Y., Hu, Y., Zhu, C., Yang, X., Shi, H., Yan, Y., Zhou, P., Ding, L., Zhang, M., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09451-4 · Cited by 2 · see citing works

Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing

Sonugür, F. G., Babahan, C., Abgarmi, S. A., & Akbulut, H. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00616-8 · Cited by 2 · see citing works

A Novel Vaccine Strategy to Prevent Cytauxzoonosis in Domestic Cats

Weerarathne, P., Maker, R., Huang, C., Taylor, B., Cowan, S. R., Hyatt, J., Selvan, M. T., Shatnawi, S., Thomas, J. E., Meinkoth, J. H., et al. (2023) · Vaccines · doi:10.3390/vaccines11030573 · Cited by 2 · see citing works

Recent Advancement of Microneedle Technique in Diagnosis and Therapy of Diseases

Kanugo, A. (2023) · International Journal of Pharmaceutical Sciences and Nanotechnology · doi:10.37285/ijpsn.2023.16.4.8 · Cited by 2 · see citing works

Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine

Choi, S. J., Lee, W., Kim, S. C., Jo, H.-Y., Park, H., Kim, H. B., Park, W., Park, S. H., Ko, J., & Lee, J. S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.019 · Cited by 2 · see citing works

FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries

Lu, S., Lee, Y.-Y., Andres, F. G. M., Moyer, D. A., & Barry, M. A. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101356 · Cited by 2 · see citing works

Achievement of maximal SARS-CoV-2 collective immunity among the Tajik population by March 2022

Popova, A. Y., Смирнов, В. С., Egorova, S. A., Abdullozoda, J. A., Мехмондустович, Р. М., Milichkina, A. M., Ivanov, V. A., Д., В. С., Ramsay, E. S., Mullodzhanova, M. M., et al. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aom-2630 · Cited by 2 · see citing works

Confronting Inequalities and Bridging the Divide: A Retrospective Study Assessment of Country-Level COVID-19 Vaccine Equality with a Cox Regression Model

Cheng, L., Chan, W. K., Lijie, Z., Chao, M. H., & Wang, Y. (2024) · Vaccines · doi:10.3390/vaccines12050552 · Cited by 2 · see citing works

Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21Preprint

Weiss, F., Kolibius, J., Freitag, P. C., Gantenbein, F., Kipar, A., & Plückthun, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.27.591433 · Cited by 2 · see citing works

Manufacturing and Control of Viral‐Vector Vaccines

Chavda, V. P., Vaghela, D. A., Barman, D., Newar, A., & Ahmed, N. (2025) · doi:10.1002/9781394271566.ch8 · Cited by 2 · see citing works

Ferritin nanoparticle complex with porcine epidemic diarrhea virus spike protein induces neutralizing antibody response against PEDV in mouse models

Tennakoon, M. S. B. W. T. M. N. S., Park, J., Lee, H., Ryu, J.-H., & Shin, H. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107509 · Cited by 1 · see citing works

Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review

Chavda, V. P., Mehta, A. A., Zafar, H., Raza, F., Paiva‐Santos, A. C., Balar, P. C., Apostolopoulos, V., & Vora, L. K. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25094 · Cited by 2 · see citing works

A recombinant lipidated receptor-binding domain is a promising self-adjuvanting antigen for mucosal vaccine

Xu, H., Wang, T., Zhang, Y., Wang, H., Yu, S., Hou, X., Zhang, B., Sun, P., Wu, J., & Liu, B. (2025) · Glycoscience & Therapy · doi:10.1016/j.glycos.2025.100019 · Cited by 1 · see citing works

The role of TgEfhc3 in Toxoplasma gondii biology and its prospects as a subunit vaccine

Tian, X., Ma, H., Wang, Q., Zhu, B., Li, Y., Zhang, J., Wang, J., Hu, Y., Li, Y., Zhang, Z., et al. (2026) · Parasites & Vectors · doi:10.1186/s13071-026-07274-8 · Cited by 1 · see citing works

First Isolation and Identification of Homologous Recombination Events of Porcine Adenovirus from Wild Boar

Oba, M., Borjigin, S., Kikuchi, F., Oi, T., Takemae, H., Ishida, H., Murakami, H., Aihara, N., Shiga, T., Kamiie, J., et al. (2022) · Viruses · doi:10.3390/v14112400 · Cited by 1 · see citing works

Mucosal immune probiotic vector vaccines: Development and prospects for application in COVID-19

Zha, R., Yi, B., Liao, C., Li, X., & Lu, J. (2023) · One Health Bulletin · doi:10.4103/2773-0344.387693 · Cited by 1 · see citing works

Construction of recombinant adenovirus-5 vector to prevent replication-competent adenovirus occurrence

Xie, W., Yuan, Y., Liu, B., & Liang, M. (2023) · Acta Virologica · doi:10.3389/av.2023.11642 · Cited by 1 · see citing works

Effect of silencing SSB1 gene on the expression of NBS1 in irradiated rat submandibular gland cells

Gao, L., Lv, Q., Huang, Y., Fan, Y., Zhao, L., Zhao, Y., Wang, X., Mo, D., Lu, H., & Wang, D. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.1.15 · Cited by 1 · see citing works

Modeling comorbidity of depression and anxiety in rats

Chkhetiani, M. (2008) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.05.187

Adenoviral Vector Immunity: Its Implications and Circumvention Strategies

Ahi, Y. S., Bangari, D. S., & Mittal, S. K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 190 · see citing works

Adenovirus Vectors: Excellent Tools for Vaccine Development

Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e6 · Cited by 125 · see citing works

Engineered adenovirus serotypes for overcoming anti-vector immunity

Dharmapuri, S., Peruzzi, D., & Aurisicchio, L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903187053 · Cited by 38 · see citing works

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239 · see citing works